Screener
Xenon Pharmaceuticals XENE Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Foreign exchange gain (loss) | (311) | 1,698 | 237 | 1,733 |
| Total other income | 11,834 | 8,897 | 19,289 | 17,015 |
| Loss before income taxes | (111,321) | (85,332) | (216,194) | (149,952) |
| Income tax recovery | 585 | 626 | 3,156 | 199 |
| Net loss | $(110,736) | $(84,706) | $(213,038) | $(149,753) |
| Other comprehensive income (loss): | ||||
| Unrealized gain (loss) on available-for-sale securities (note 5) | (1,445) | 949 | (2,991) | 1,725 |
| Comprehensive loss | $(112,181) | $(83,757) | $(216,029) | $(148,028) |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's income tax?
- Xenon Pharmaceuticals (XENE) reported income tax of -$585K in Q2 2026.
- How has Xenon Pharmaceuticals's income tax changed year-over-year?
- Xenon Pharmaceuticals's income tax increased by 6.5% year-over-year, from -$626K to -$585K.
- What is the long-term trend for Xenon Pharmaceuticals's income tax?
- Over 3 years (2022 to 2025), Xenon Pharmaceuticals's income tax has grown at a 105.0% compound annual growth rate (CAGR), from $118K to $1.02M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Xenon Pharmaceuticals's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude